News

News and Press Releases
Our Research Approach CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method

The Cystic Fibrosis Foundation’s investment will go toward conducting preclinical research on a novel gene delivery vehicle. If successful, this gene delivery method could overcome some of the biggest challenges to delivering a gene therapy into the lung cells of people with cystic fibrosis.

| 2 min read
About the CF Foundation | Our Research Approach CF Foundation Provides Additional Funding to Carmine Therapeutics for Early-Stage Research Into Potential Genetic Therapy

The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.

| 4 min read
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis

Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab

| 4 min read
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Invests $5 Million in Sionna Therapeutics to Develop New CFTR Modulator Therapy

New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease

| 3 min read
Clinical Trials | Our Research Approach CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy

The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.

| 4 min read
Our Research Approach CF Foundation Awards $1 Million to Felix Biotechnology to Develop Novel Phage Therapy

The Foundation’s award will support preclinical studies of a potential phage therapy to treat resistant Pseudomonas infections.

| 2 min read
About the CF Foundation | Our Research Approach CF Foundation Exceeds Initial $100M Infection Research Initiative Funding

This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.

| 7 min read
About the CF Foundation | Clinical Trials | Our Research Approach Cystic Fibrosis Foundation Awards Up to $3.5M to Arrevus Inc. to Develop Treatment for Pulmonary Exacerbations

The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.

| 1 min read
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research

Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
 

| 5 min read
About the CF Foundation | Clinical Trials | Our Research Approach CF Foundation Awards Up to $4.7M to EnBiotix Inc. to Develop Inhaled Antibiotic to Treat Pseudomonas

The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.

| 2 min read